These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 28786345)
21. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer. Wahi A; Manchanda N; Jain P; Jadhav HR Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545 [TBL] [Abstract][Full Text] [Related]
22. Binding Assays for Bromodomain Proteins: Their Utility in Drug Discovery in Oncology and Inflammatory Disease. Zolotarjova NI; Wynn R Curr Protoc Pharmacol; 2018 Mar; 80(1):3.16.1-3.16.14. PubMed ID: 30040205 [TBL] [Abstract][Full Text] [Related]
23. Small-molecule BET inhibitors in clinical and preclinical development and their therapeutic potential. Yu L; Wang Z; Zhang Z; Ren X; Lu X; Ding K Curr Top Med Chem; 2015; 15(8):776-94. PubMed ID: 25732788 [TBL] [Abstract][Full Text] [Related]
24. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270 [TBL] [Abstract][Full Text] [Related]
25. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. Yang CY; Qin C; Bai L; Wang S Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858 [TBL] [Abstract][Full Text] [Related]
26. The Functions of BET Proteins in Gene Transcription of Biology and Diseases. Cheung KL; Kim C; Zhou MM Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900 [TBL] [Abstract][Full Text] [Related]
27. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues. Jiang H; Xing J; Wang C; Zhang H; Yue L; Wan X; Chen W; Ding H; Xie Y; Tao H; Chen Z; Jiang H; Chen K; Chen S; Zheng M; Zhang Y; Luo C Org Biomol Chem; 2017 Nov; 15(44):9352-9361. PubMed ID: 29087414 [TBL] [Abstract][Full Text] [Related]
28. The emerging role of BET inhibitors in breast cancer. Andrikopoulou A; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F Breast; 2020 Oct; 53():152-163. PubMed ID: 32827765 [TBL] [Abstract][Full Text] [Related]
29. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088 [TBL] [Abstract][Full Text] [Related]
31. Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer. Xue X; Zhang Y; Wang C; Zhang M; Xiang Q; Wang J; Wang A; Li C; Zhang C; Zou L; Wang R; Wu S; Lu Y; Chen H; Ding K; Li G; Xu Y Eur J Med Chem; 2018 May; 152():542-559. PubMed ID: 29758518 [TBL] [Abstract][Full Text] [Related]
32. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine. Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024 [TBL] [Abstract][Full Text] [Related]
33. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment. Ali I; Lee J; Go A; Choi G; Lee K Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121 [TBL] [Abstract][Full Text] [Related]
34. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases. Padmanabhan B; Mathur S; Manjula R; Tripathi S J Biosci; 2016 Jun; 41(2):295-311. PubMed ID: 27240990 [TBL] [Abstract][Full Text] [Related]
35. BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. Markowski MC; De Marzo AM; Antonarakis ES Expert Opin Investig Drugs; 2017 Dec; 26(12):1391-1397. PubMed ID: 29032717 [TBL] [Abstract][Full Text] [Related]
36. Bromodomain inhibitors and cancer therapy: From structures to applications. Pérez-Salvia M; Esteller M Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230 [TBL] [Abstract][Full Text] [Related]
37. Cytoprotective, Cytotoxic and Cytostatic Roles of Autophagy in Response to BET Inhibitors. Elshazly AM; Gewirtz DA Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628849 [TBL] [Abstract][Full Text] [Related]
38. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases. Morgado-Pascual JL; Rayego-Mateos S; Tejedor L; Suarez-Alvarez B; Ruiz-Ortega M Front Pharmacol; 2019; 10():1315. PubMed ID: 31780938 [TBL] [Abstract][Full Text] [Related]
39. BET inhibitors: a novel epigenetic approach. Doroshow DB; Eder JP; LoRusso PM Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216 [TBL] [Abstract][Full Text] [Related]
40. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]